• Merck and Gilead discontinued the Phase 3 KEYNOTE-D46/EVOKE-03 trial in first-line metastatic non-small cell lung cancer.
• The Trodelvy-Keytruda combination showed a directional improvement in delaying disease worsening, but missed the study’s primary efficacy bar.
• An independent monitoring committee judged a meaningful survival benefit was unlikely, driving the decision to stop the study.
• Safety matched the known profiles of both drugs, with no new signals flagged.
• Results have not been presented yet; the companies plan to present the data at a future medical meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260608789974) on June 08, 2026, and is solely responsible for the information contained therein.